• Logo
  • SBMUJournals

Monomethyl Auristatin E, a Potent Cytotoxic Payload for Development of Antibody-Drug Conjugates against Breast Cancer

Meghdad Abdollahpour-alitappeh, Amir Amanzadeh, Fatemeh Heidarnejad, Mahdi Habibi-Anbouhi, Majid Lotfinia, Sepand Razavi-vakhshourpour, Saeed Jahandideh, Hamid Najminejad, Saeed Balalaie, Mohsen Abolhassani




Background: Breast cancer is a heterogeneous disease characterized by differential responses to targeted and chemotherapeutic agents. Antibody-drug conjugates are one of the promising strategies for the treatment of breast cancer. Monomethyl auristatin E (MMAE) is a highly potent microtubule inhibitor and a common payload used for development of antibody-drug conjugates. The purpose of this study was to investigate the cytotoxic effects of MMAE on breast cancer cell lines.

Materials and Methods: MDA-MB-468 and MDA-MB-453 cells were treated with MMAE at various concentrations (1, 10, 100, and 1000 ng/ml), and cytotoxicity was measured after 48 and 72 hours using an MTT assay.

Results: Our findings indicated that MMAE possesses dose- and time-dependent cytotoxic activities against human breast cancer cells. The morphological features of the treated cells were supportive of the cytotoxic activity of MMAE. The results of the MTT assay showed that MMAE has a significant cytotoxicity against MDA-MB-468 and, to a lesser degree, MDA-MB-453 cells.

Conclusion: MMAE can be used as a highly cytotoxic payload for development of antibody-drug conjugates against breast cancer.


Monomethyl auristatin E, cytotoxicity, Antibody-drug conjugate, MDA-MB-468, MDA-MB-453


Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015;65(2):87-108.

Hong YS, Deming SL, Gao YT, et al. A two-stage case-control study of EGFR polymorphisms and breast cancer risk. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2009;18(2):680-683.

Sledge GW, Mamounas EP, Hortobagyi GN, Burstein HJ, Goodwin PJ, Wolff AC. Past, present, and future challenges in breast cancer treatment. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2014;32(19):1979-1986.

Pohlmann PR, Mayer IA, Mernaugh R. Resistance to Trastuzumab in Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009;15(24):7479-7491.

Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annual review of medicine. 2013;64:15-29.

Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nature biotechnology. 2003;21(7):778-84.

Dubowchik GM, Walker MA. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharmacology & therapeutics. 1999;83(2):67-123.

Wagner-Rousset E, Janin-Bussat MC, Colas O, et al. Antibody-drug conjugate model fast characterization by LC-MS following IdeS proteolytic digestion. mAbs. 2014;6(1):273-285.

Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nature reviews. Immunology. 2010;10(5):345-52.

Behrens CR, Ha EH, Chinn LL, et al. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs. Molecular pharmaceutics. 2015;12(11):3986-98.

Jackson D, Atkinson J, Guevara CI, et al. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates. PloS one. 2014;9(1):e83865.

Lu J, Jiang F, Lu A, Zhang G. Linkers Having a Crucial Role in Antibody-Drug Conjugates. International journal of molecular sciences. 2016;17(4):561.

Diamantis N, Banerji U. Antibody-drug conjugates--an emerging class of cancer treatment. British journal of cancer. 2016;114(4):362-7.

Searcey M. Duocarmycins--natures prodrugs? Current pharmaceutical design. 2002;8(15):1375-89.

Hartley JA. The development of pyrrolobenzodiazepines as antitumour agents. Expert opinion on investigational drugs. 2011;20(6):733-44.

Kim EG, Kim KM. Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics. Biomolecules & therapeutics. 2015;23(6):493-509.

Dosio F, Brusa P, Cattel L. Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components. Toxins. 2011;3(7):848-83.

Sineh Sepehr K, Baradaran B, Mazandarani M, Yousefi B, Abdollahpour Alitappeh M, Khori V. Growth-Inhibitory and Apoptosis-Inducing Effects of Punica granatum L. var. spinosa (Apple Punice) on Fibrosarcoma Cell Lines. Advanced pharmaceutical bulletin. 2014;4(Suppl 2):583-90.

Tan M, Yu D. Molecular mechanisms of erbB2-mediated breast cancer chemoresistance. Advances in experimental medicine and biology. 2007;608:119-29.

Yu D, Liu B, Jing T, et al. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene. 1998;16(16):2087-94.

Sellappan S, Grijalva R, Zhou X, et al. Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer research. 2004;64(10):3479-85.

Liu Y, Peng H, Zhang JT. Expression profiling of ABC transporters in a drug-resistant breast cancer cell line using AmpArray. Molecular pharmacology. 2005;68(2):430-8.

Huang R, Murry DJ, Kolwankar D, Hall SD, Foster DR. Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines. Biochemical pharmacology. 2006;71(12):1695-704.

O'Brien C, Cavet G, Pandita A, et al. Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer research. 2008;68(13):5380-9.

Yao X, Jiang J, Wang X, et al. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity. Breast cancer research and treatment. 2015;153(1):123-33.

Ott PA, Hamid O, Pavlick AC, et al. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32(32):3659-66.

Ma D, Hopf CE, Malewicz AD, et al. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006;12(8):2591-6.

van de Donk NW, Dhimolea E. Brentuximab vedotin. mAbs. 2012;4(4):458-65.

DOI: https://doi.org/10.22037/nbm.v5i3.15523